News & analysis on the clinical development and manufacture of large molecule drugs
News from Recipharm, Aesica and SMS Oncology – People on the move
By Dan Stanton
- Last updated on
Dr. Hans Lennernäs
Recipharm Pharmaceutical Development has announced the appointment of Dr. Hans Lennernäs to the operating board of Recipharm Pharmaceutical Development.
Dr. Lennernäs is presently Professor of Biopharmaceutics at Uppsala University but has previously served as Principal Investigator in an extensive collaboration with the US Food Drug & Administration as well as cofounding several companies, including Duocart Pharma and Lidds.
“His track record of successfully inventing and developing several novel drug delivery systems that are currently in pre-clinical phase and in preparation for phase I, II and III clinical trials, makes him an excellent addition to the Board,” said Maria Lundberg, General Manager at Recipharm.
She continued: “I look forward to Recipharm benefiting from his Board level contribution and insights that will help the company perpetuate its track record of commercial success.”
Contract manufacturing organisation Aesica has announced the appointment of Jarrett Palmer as Operations Director of its formulated products business unit business.
Palmer will be responsible of the management of Aesica’s facility in Queenborough, UK as well as recently acquired sites in Germany and Italy.
Chris Gowland, Managing Director of Formulated Products at Aesica, expressed his delight with the appointment. “He brings significant experience with a long and established track record of managing sites for global CMOs.”
CRO Specialized Medical Services-Oncology (SMS Oncology) has announced a number of changes to its management team, including appointing Edwin Klumper (pictured) as CEO.
In a total shakeup of the team, Philine van den Tol has been promoted to Chief Operating Officer, Wouter Wijker to Managing Director Biometrics Unit, and Raymond Hoffmans to Director Consultancy.
Klumper said: “These changes reflect our steady growth and mark our next step.”
Klumper is replacing Eric van der Putten who leaves his role as CEO to become Chief Business Development Officer, responsible for driving new business opportunities and growing SMS Oncology’s client base.
“Our clients will benefit discussing their new cancer studies with Eric who brings to the table 30+ years of experience in running phase I and II cancer trials in close collaboration with the top tier of oncologists,” said new CEO Edwin Klumper. “His experience and operational insights will be of great value to our clients in achieving their objectives.”
In other industry news:
Special life sciences advisory firm, SkilaMederi has announced a new appointment to its Executive Management Team as Raymond Joske becomes Chief Commercial Officer.
Joske has worked at Bristol-Myers Squibb and Merck in his 28 years in the life sciences industry.
CEO Kilian Weiss said: "We look forward to his contribution as SkilaMederi embarks on this next stage of growth."
CRO PPD has announced three new Therapeutic Heads in its expansion of its global product department. Drs. Daniel J. Burch, Puneet Mohan and Alan M. Solinger all join the team in the areas of central nervous system, cardiovascular and rheumatology/immunology respectively.
Each head will play key roles in addressing critical drug development challenges.